This archive report was first published on 17 June 2020.
On June 16, 2020, a groundbreaking clinical trial revealed that administering low doses of the generic steroid dexamethasone to patients hospitalized with COVID-19 significantly reduced death rates among those with the most severe cases of infection.
According to the trial's results, described as a
